Helsinn Healthcare

What Helsinn Healthcare does

Helsinn Healthcare S.A. is a privately-held Swiss pharmaceutical company headquartered in Lugano and founded in 1976 as a third-generation family-owned enterprise (Braglia family). The company develops, manufactures, and commercializes a six-product branded portfolio focused on supportive care, oncology, and dermato-oncology, anchored by the Akynzeo fixed combination antiemetic franchise (NK1 + 5-HT3 receptor antagonists) for chemotherapy-induced nausea and vomiting, the Alozi/Onicit/Paloxi palonosetron franchise with 20+ years on market, Adlumiz (first-and-only approval in Japan for cancer cachexia), Valchlor/Ledaga for mycosis fungoides cutaneous T-cell lymphoma, Arokaris (Japan-only injectable), and Aulin (nimesulide NSAID, 30+ countries). Manufacturing is concentrated at a state-of-the-art facility in Ireland (Helsinn Birex Pharmaceuticals), with a wholly-owned U.S. commercial subsidiary (Helsinn Therapeutics), offices in Beijing, and a commercial presence across 90 countries delivered through a network of regional distribution and licensing partners including ESTEVE (DACH), MagnaPharm (CEE), and Knight Therapeutics.

Helsinn operates an integrated licensing business model that combines in-licensing, partnering, and direct commercialization. Its go-to-market is hybrid: direct enterprise field sales in the U.S. and Japan, with channel-partner distribution in most international markets — a capital-light structure that limits fixed-cost exposure while extending reach. End-customers are oncology patients and healthcare providers, with the firm targeting pain points including chemotherapy-induced nausea and vomiting, cancer cachexia, cutaneous T-cell lymphoma, and acute pain management.

The technology platform combines proprietary life-cycle development, regulatory, and supply-chain capabilities with a proprietary compound library of structurally diverse biologically-active molecules. In February 2026, Helsinn added a generative-AI drug discovery layer via a strategic R&D collaboration with InVirtuoLabs SA, applying the InVirtuoGEN platform to design and optimize novel preclinical candidates. Recent strategic activity also includes a co-owned U.S. patent (issued March 2026) covering AC01 in heart failure with reduced ejection fraction, IP protection to 2042, signaling entry into cardiovascular indications through partnered assets.

Name

Helsinn Healthcare

Legal name

Helsinn Healthcare S.A.

Website

https://helsinn.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Helsinn Healthcare is a privately-held, third-generation family-owned Swiss pharmaceutical company founded in 1976 that develops, manufactures, and commercializes supportive care, oncology, and dermato-oncology products — anchored by the Akynzeo antiemetic franchise — serving cancer patients in 90 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Cancer Supportive Care)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Medical Oncology (HLAKAFAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Specialty pharmaceuticals
• Cancer supportive care
• Chemotherapy-induced nausea
• Antiemetic medications
• Oncology pharmaceuticals

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Product Commercialization: Helsinn builds, manufactures, launches, and commercializes pharmaceutical products globally to improve quality of life for patients with cancer and chronic diseases. The company operates a unique integrated licensing business model.
2. Manufacturing and Supply: State-of-the-art manufacturing plant in Ireland handles production, combined with comprehensive technical organization covering development, regulatory affairs, and supply chain operations.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Helsinn Healthcare is a global pharmaceutical company that builds, manufactures, launches, and commercializes products focused on supportive care, oncology, and dermato-oncology for patients with cancer and chronic diseases. Its portfolio centers on branded prescription drugs for chemotherapy-induced nausea and vomiting (AKYNZEO, ALOXI/Onicit/Paloxi, Arokaris), cancer cachexia (Adlumiz), mycosis fungoides cutaneous T-cell lymphoma (Valchlor/Ledaga), and pain management (Aulin/Mesulid/Nisulid), supported by in-house manufacturing, an integrated licensing business model, and a proprietary compound library.

Product overview

Helsinn Healthcare operates as a global pharmaceutical company focused on supportive care, oncology, and dermato-oncology. The company's portfolio consists of six core branded pharmaceutical products: Akynzeo® (fixed combination antiemetic for CINV), Aloxi®/Onicit®/Paloxi® (palonosetron for CINV and PONV), Arokaris® (fosnetupitant injection for CINV, Japan), Adlumiz® (anamorelin for cancer cachexia, Japan), Valchlor®/Ledaga® (mechlorethamine gel for MF-CTCL), and Aulin®/Mesulid®/Nisulid® (nimesulide NSAID for pain). The portfolio centers on supportive care products for cancer patients, with two products addressing chemotherapy-induced nausea and vomiting, one for cancer cachexia, and one for cutaneous T-cell lymphoma, plus a pain management NSAID.

Differentiator

Problem solved

Functional benefit

Brands

• Akynzeo: Fixed combination antiemetic for chemotherapy-induced nausea and vomiting prevention
• Aloxi/Onicit/Paloxi
• Arokaris
• Adlumiz
• Valchlor/Ledaga
• Aulin/Mesulid/Nisulid

Products and services

• Akynzeo First and only fixed-combination antiemetic composed of an NK1 receptor antagonist (netupitant or fosnetupitant) and a 5-HT3 receptor antagonist (palonosetron), approved for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly and moderately emetogenic chemotherapy.
• Aloxi / Onicit / Paloxi Palonosetron-based 5-HT3 antagonist used for over 20 years to prevent chemotherapy-induced nausea and vomiting (CINV); also approved at lower doses for post-operative nausea and vomiting (PONV). Available as injection for adults and children aged 1 month and older and as capsules for adults.
• Arokaris Injectable formulation of fosnetupitant (235 mg), a water-soluble phosphorylated prodrug of netupitant, used in combination with corticosteroids and 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting; approved and available in Japan only.
• Adlumiz First and only product approved in Japan for cancer cachexia, containing anamorelin hydrochloride, an oral selective ghrelin receptor agonist for malignancy-associated weight loss and anorexia; approved for non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.
• Valchlor / Ledaga Topical gel formulation of mechlorethamine (chlormethine), a bifunctional alkylating agent for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL); first and only topical therapy purposely developed and indicated as first-line therapy for MF-CTCL.
• Aulin / Mesulid / Nisulid Nimesulide-based nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, indicated for acute pain and primary dysmenorrhoea in adolescents and adults above 12 years old; available in more than 30 countries but not in the United States.

Quantifiable outcome

• Single-dose AKYNZEO provides long-lasting protection from CINV during both acute and delayed phases
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• AnaCardio ABcoreStrategic or Co-development Partner · 11 March 2026Co-ownership of U.S. Patent No. 12,569,476 covering AC01 for treating heart failure with reduced ejection fraction (HFrEF). Patent provides IP protection in the United States until June 2, 2042, strengthening long-term exclusivity and layered IP position for AC01 in the world's largest pharmaceutical market.
• InVirtuoLabs SAcoreStrategic or Co-development Partner · 25 February 2026Strategic R&D collaboration applying InVirtuoLabs' AI-driven generative chemistry platform (InVirtuoGEN) to design, optimize, and prioritize novel drug candidates using Helsinn's proprietary compound library for preclinical development in oncology and chronic disease indications. Founded in 2024, InVirtuoLabs is a Lugano-based biotech startup.
• MagnaPharmcoreChannel Partner/ Reseller/ Distributor · 11 February 2026Long-term Licence, Distribution and Supply Agreement for AKYNZEO and ALOXI across five Central and Eastern European countries: Poland, Romania, Czech Republic, Slovakia, and Hungary. Both products indicated for chemotherapy-induced nausea and vomiting treatment in adult patients. MagnaPharm operates across 17 CEE countries.
• ESTEVEcoreChannel Partner/ Reseller/ Distributor · 9 February 2026Expansion of Distribution and Licence Agreement for AKYNZEO and ALOXI to Austria. Partnership spans over 15 years with previous agreements covering Germany. ESTEVE is an international pharma company focused on highly specialized treatments with affiliates in Spain, Portugal, Italy, Germany, France, UK, and USA.
• Knight TherapeuticscoreChannel Partner/ Reseller/ Distributor · 28 January 2025Exclusive License, Distribution, and Supply Agreement for Onicit (palonosetron). Expands relationship between Helsinn and Knight Therapeutics for supportive care products in select markets.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Heron Therapeutics: U.S.-listed specialty pharma with overlapping focus on CINV prevention (CINVANTI/SUSTOL) and postoperative pain. Most directly comparable to Helsinn in specialty supportive-care oncology commercialization.
• Eagle Pharmaceuticals: Specialty pharma focused on oncology and critical care injectables, with overlapping CINV and supportive-care assets. Comparable in size and product-portfolio depth to Helsinn's branded franchise approach.
• Mundipharma: Privately held specialty pharma operating via in-licensing and regional partnership model closely mirroring Helsinn's integrated licensing approach, with overlapping portfolios in pain and supportive care.

Broad incumbents

• Eisai Co., Ltd. Original developer of Aloxi (palonosetron) and a broader Japanese-headquartered pharma with significant oncology and supportive-care presence. Comparable as Helsinn's historic licensing counterparty and as a broader supportive-care incumbent.
• Helsinn's partner: Merck & Co. (EMEND): Markets EMEND (aprepitant), an NK1 receptor antagonist directly competing with Helsinn's AKYNZEO in the CINV setting. A large-pharma incumbent in the same therapeutic indication.
• GSK (Tesaro/Zofran): Owns Zofran (ondansetron) and acquired Tesaro with CINV assets (VARUBI), placing it as a broad incumbent competing across the acute and delayed CINV phases where Helsinn's palonosetron and netupitant franchises operate.
• Vifor Pharma: Swiss-headquartered specialty pharma with comparable size, in-licensing orientation, and European commercial infrastructure. Useful comparable for Helsinn's Swiss base, distribution model, and specialty therapeutic focus.
• Ipsen: European specialty pharma with a meaningful oncology and supportive-care footprint and a similar geographic/regulatory profile to Helsinn. Comparable in product-portfolio breadth and mid-sized European pharma positioning.

Regional players

• Specialised Therapeutics Asia: Asia-Pacific-focused specialty oncology distributor that in-licenses branded therapeutics from Western developers. Closely comparable distribution role to Helsinn's partner network in select markets.
• Knight Therapeutics: Canadian specialty pharma that already distributes Helsinn's Onicit and similar in-licensing oncology supportive-care products across Latin America and other markets. Directly comparable as a counterparty and competitor for Western-developed oncology assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/helsinngroup
• YouTubevimeo.com/helsinn
• LinkedInlinkedin.com/company/helsinn-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helsinn Healthcare